Fibrin-stabilizing factor inhibitors.
D000588:Amines / Q000494:pharmacology; D001665:Binding Sites; D001777:Blood Coagulation / Q000187:drug effects*; D001778:Blood Coagulation Disorders / Q000188:drug therapy; D002103:Cadaverine / Q000494:pharmacology; D055598:Chemical Phenomena; D002621:Chemistry; D003509:Cyclohexanecarboxylic Acids / Q000494:pharmacology; D003619:Dansyl Compounds / Q000494:pharmacology; D004789:Enzyme Activation; D005176:Factor XIII; D005337:Fibrin; D005342:Fibrinolysis / Q000187:drug effects; D005973:Glutamine; D006801:Humans; D008744:Methylamines / Q000494:pharmacology; D009281:Naphthalenes / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013449:Sulfonamides / Q000494:pharmacology; D013927:Thrombosis / Q000188:drug therapy / Q000517:prevention & control; D014166:Transferases / Q000037:antagonists & inhibitors*
D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D003619:Dansyl Compounds; D008744:Methylamines; D009281:Naphthalenes; D013449:Sulfonamides; D005973:Glutamine; D005337:Fibrin; D005176:Factor XIII; D014166:Transferases; D002103:Cadaverine